Compass Therapeutics, Inc. filed a Form 8-K with the SEC on September 22, 2026, disclosing that it received regulatory feedback from the FDA relating to tovecimig in patients with biliary tract cancer, with the full details contained in an attached press release.

Key Highlights

  • FDA Feedback Received: Compass Therapeutics disclosed regulatory feedback from the FDA relating to tovecimig in patients with biliary tract cancer ("BTC").
  • Drug Candidate: Tovecimig is described in the filing as a potential treatment option for BTC patients in the second-line setting.
  • COMPANION-002 Study: The company referenced its COMPANION-002 Randomized Phase 2/3 Study, with intentions to discuss the data with the FDA ahead of a planned BLA submission.
  • Conference Presentation: According to the filing, the company expects to present the complete dataset at a medical conference in 2026.
  • Disclosure Type: The information was furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
  • Signed by: The report was signed by Neil Lerner, Chief Accounting Officer, on September 22, 2026.

Compass Therapeutics Discloses FDA Regulatory Feedback on Tovecimig in BTC

Compass Therapeutics, Inc. (NASDAQ:CMPX), headquartered at 80 Guest Street, Suite 601, Boston, Massachusetts, filed a current report on September 22, 2026, under Item 7.01 (Regulation FD Disclosure). According to the filing, the company issued a press release on the same date announcing that it had received regulatory feedback from the FDA relating to tovecimig in patients with biliary tract cancer. The full text of that press release was attached as Exhibit 99.1 and incorporated by reference.

The filing references the COMPANION-002 Randomized Phase 2/3 Study and states that Compass intends to discuss the data from that study with the FDA in advance of a planned Biologics License Application (BLA) submission. The company also indicated, according to the filing, an expectation to present the complete dataset at a medical conference in 2026. These points are characterized in the filing as forward-looking statements subject to risks including the company's ability to raise additional funding, inherent uncertainties in developing product candidates, and competition in the industry.

As disclosed in the filing, the information furnished under Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Exchange Act," and is not deemed incorporated by reference in any filing under the Securities Act or the Exchange Act unless expressly set forth by specific reference. The filing further notes that Compass "assumes no obligation to update the forward-looking statements... except as required by law."

What Was Disclosed

Compass Therapeutics reported receipt of FDA regulatory feedback on tovecimig for biliary tract cancer patients, referenced the COMPANION-002 study, and indicated plans for a BLA submission discussion and a full dataset presentation at a medical conference in 2026.